Summary & Overview
Intraocular Procedures with CC/MCC: Inpatient Reimbursement Overview
DRG 116 groups inpatient admissions for intraocular surgical procedures with a Complication or Comorbidity or Major Complication or Comorbidity, covering more complex or complicated eye operations. It matters for inpatient reimbursement because the Complication or Comorbidity and Major Complication or Comorbidity designations increase the Medicare Severity Diagnosis-Related Group payment weight and therefore hospital payment under Centers for Medicare & Medicaid Services rules.
DRG 116 Overview
DRG 116 covers inpatient hospital admissions for intraocular surgical procedures performed for a range of eye conditions when there is a documented Complication or Comorbidity or Major Complication or Comorbidity. These cases typically include complex cataract extractions, intraocular lens procedures, and other microsurgical interventions complicated by additional diagnoses that increase resource use. This Diagnosis-Related Group matters for Medicare payment because the presence of Complication or Comorbidity or Major Complication or Comorbidity elevates the relative payment weight and affects hospital reimbursement. Accurate coding of the principal procedure and coexisting diagnoses directly influences payment under Centers for Medicare & Medicaid Services inpatient prospective payment policies.
Clinical Trials
- Acute intraoperative device and technique trials: randomized or prospective studies comparing alternative intraocular surgical techniques (for example, variations in vitrectomy gauge, lens implantation approaches, or intraocular tamponade agents) in patients undergoing inpatient intraocular procedures with significant comorbidity. These trials typically enroll patients with complex pathology (traumatic globe injuries, dense cataracts with ocular comorbidities, advanced diabetic retinopathy, or emergency retinal detachments) to assess short-term surgical success, complication rates, and need for reoperation. Results inform surgeons and hospital administrators about procedural efficacy, intraoperative safety, and resource utilization during the index admission, which directly affects DRG-related inpatient LOS and complication-related cost drivers.
- Comparative effectiveness and perioperative management studies: observational cohort studies or randomized trials evaluating different perioperative care pathways (for example, antibiotic prophylaxis regimens, anticoagulation management strategies, or anesthesia approaches) in medically complex patients receiving intraocular procedures with CC/MCC. These studies focus on patients who have significant medical comorbidities (cardiovascular disease, diabetes with end-organ damage, or chronic anticoagulation) that raise the risk of perioperative complications, aiming to reduce postoperative infections, hemorrhage, or systemic events. Findings are relevant to payers and providers because optimized perioperative protocols can lower complication frequencies, readmissions, and total inpatient costs associated with DRG 116 episodes.
- Post-discharge outcomes and functional recovery research: longitudinal studies and registry-based outcomes research tracking visual function, quality of life, and readmission or reoperation rates after inpatient intraocular procedures in high-risk populations (elderly patients, those with multiple chronic conditions, or those who required emergency inpatient surgery). These studies examine medium- to long-term outcomes such as visual acuity recovery, late complications (endophthalmitis, recurrent detachment), and healthcare utilization after discharge to identify predictors of poor recovery and targets for transitional care. Results help payers and hospital systems design post-acute care pathways, discharge planning, and follow-up schedules that may reduce readmissions and downstream costs tied to DRG 116 admissions.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.